Vernalis PLC: Notice of Results for Six Months Ended

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
75
Vernalis PLC: Notice of Results for Six Months Ended 31/12/2016

WINNERSH, UNITED KINGDOM--(Marketwired - Jan 30, 2017) - Vernalis PLC ( LSE : VER ); ( OTC PINK : VNLPY )

30 January 2017

Vernalis plc ("Vernalis" or the "Company")

Notice of Results for the Six Months Ended 31 December 2016

Vernalis plc ( LSE : VER ) announces that its unaudited interim results for the six months ended 31 December 2016 will be released on Tuesday, 21 February 2017. The results announcement will be distributed at 7:00 AM (UK) and will be available to download from www.vernalis.com .

Following the results announcement, the Company will host an analyst presentation and concurrent conference call at 9:30 am (UK) at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. Please contact Tim Stamper at FTI Consulting +44 (0) 20 3727 1000 for details.

-- ends --

Enquiries:

     
Vernalis plc:   +44 (0) 118 938 0015
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer    
Canaccord Genuity Limited (Nominated Adviser & Joint Broker):   +44 (0) 20 7523 8000
Rupert Winckler Henry Fitzgerald-O'Connor Emma Gabriel    
Shore Capital (Joint Broker):   +44 (0) 20 7408 4090
Bidhi Bhoma Toby Gibbs    
FTI Consulting:   +44 (0) 20 3727 1000
Ben Atwell Simon Conway Stephanie Cuthbert Matthew Moss    

Notes to Editors

About Vernalis Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra ® XR targeting the US prescription cough cold market; MOXATAG ® , a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

For further information about Vernalis, please visit www.vernalis.com

Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.

Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 5

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 4

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 4

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 2

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 3

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 4

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Dynamics of Texas Instruments' Short Interest

Updated Category News Views 124

Delving into the Short Interest of Texas Instruments Texas Instruments TXN has recently seen a notable decrease in its short interest, which has fallen by 12.71% since the last report. As of the latest figures, the company reported that approximately 16.83 million shares have been sold short, representing around 2.06% of all shares available for trading. With these...

Continue Reading
Nuvoton Launches Revolutionary 1.7W Indigo Laser Diode

Updated Category News Views 343

Nuvoton Introduces an Innovative Indigo Laser Diode Nuvoton Technology Corporation Japan, widely known as NTCJ, has celebrated another milestone in laser technology with the introduction of their groundbreaking indigo semiconductor laser. This innovative product boasts an impressive optical output power of 1.7 W and operates at a wavelength of 420 nm, making it a...

Continue Reading
Exploring the Surge in Japanese Stocks Amid Political Changes

Updated Category News Views 121

Japanese Stocks Reach New Heights In recent times, Japanese stocks have soared to impressive new highs, buoyed by a combination of economic factors and political dynamics. A notable factor in this surge has been a weakening yen, coupled with increasing bond yields, coinciding with discussions around potential snap elections initiated by Prime Minister Sanae Takaichi....

Continue Reading
TGS Enhances Summer Operations in Northern Europe with Vessels

Updated Category News Views 183

TGS Expands Summer Operations in Northern Europe TGS, a renowned provider of energy data and intelligence, has reported an exciting summer season ahead in Northern Europe. This year, the company has not only increased its acquisition capacity but has also enhanced its operational efficiency with the deployment of four acquisition vessels in the region: three seismic...

Continue Reading
Zentalis Pharmaceuticals Welcomes James B. Bucher as CLO

Updated Category News Views 152

Zentalis Pharmaceuticals Strengthens Leadership with New Appointment In a significant move, Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on innovative therapies for cancer treatment, is thrilled to announce the appointment of James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary. This strategic step comes...

Continue Reading